Biogen Inc. (BVMF:BIIB34)
Brazil · Delayed Price · Currency is BRL 161.80
-0.20 (-0.12%)
At close: Feb 5, 2026
Biogen Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 9,891 | 9,676 | 9,836 | 10,173 | 10,982 |
| 9,891 | 9,676 | 9,836 | 10,173 | 10,982 | |
Revenue Growth (YoY) | 2.22% | -1.62% | -3.32% | -7.36% | -18.32% |
Cost of Revenue | 2,082 | 2,129 | 2,533 | 2,278 | 2,110 |
Gross Profit | 7,808 | 7,547 | 7,302 | 7,895 | 8,872 |
Selling, General & Admin | 2,434 | 2,387 | 2,502 | 2,409 | 2,680 |
Research & Development | 1,753 | 1,954 | 2,442 | 2,229 | 2,497 |
Amortization of Goodwill & Intangibles | 507.1 | 386.5 | 240.6 | 246.3 | 252 |
Other Operating Expenses | 290.2 | 254.4 | 218.8 | -7.4 | 7.2 |
Operating Expenses | 4,984 | 4,982 | 5,403 | 4,877 | 5,436 |
Operating Income | 2,824 | 2,566 | 1,899 | 3,019 | 3,436 |
Interest Expense | -267.5 | -250.3 | -246.9 | -246.6 | -250.4 |
Interest & Investment Income | 125 | 67.6 | 276.5 | 89.3 | 11 |
Earnings From Equity Investments | - | - | - | 2.6 | 34.9 |
Currency Exchange Gain (Loss) | -28.6 | -30.9 | -50.4 | -35.5 | -22.4 |
Other Non Operating Income (Expenses) | -110.1 | -26.5 | -1.7 | -7.1 | -4 |
EBT Excluding Unusual Items | 2,543 | 2,325 | 1,876 | 2,821 | 3,205 |
Merger & Restructuring Charges | -295.3 | -258.2 | -271.7 | -131.1 | - |
Gain (Loss) on Sale of Investments | -19.7 | -100.4 | -291.2 | 1,228 | -824.9 |
Gain (Loss) on Sale of Assets | - | 88.6 | - | 503.7 | - |
Asset Writedown | -60.8 | -60.2 | - | -119.6 | -629.3 |
Legal Settlements | -104.9 | - | - | -917 | - |
Other Unusual Items | -33.6 | -27.7 | - | 209.1 | 47.5 |
Pretax Income | 1,557 | 1,906 | 1,297 | 3,594 | 1,780 |
Income Tax Expense | 263.6 | 273.8 | 135.3 | 632.8 | 52.5 |
Earnings From Continuing Operations | 1,293 | 1,632 | 1,162 | 2,962 | 1,728 |
Minority Interest in Earnings | - | - | -0.4 | 85.3 | -171.5 |
Net Income | 1,293 | 1,632 | 1,161 | 3,047 | 1,556 |
Net Income to Common | 1,293 | 1,632 | 1,161 | 3,047 | 1,556 |
Net Income Growth | -20.79% | 40.57% | -61.89% | 95.80% | -61.10% |
Shares Outstanding (Basic) | 147 | 146 | 145 | 145 | 149 |
Shares Outstanding (Diluted) | 147 | 146 | 146 | 146 | 150 |
Shares Change (YoY) | 0.82% | 0.21% | -0.27% | -2.41% | -7.25% |
EPS (Basic) | 8.83 | 11.21 | 8.02 | 20.97 | 10.44 |
EPS (Diluted) | 8.79 | 11.18 | 7.97 | 20.87 | 10.40 |
EPS Growth | -21.38% | 40.28% | -61.81% | 100.67% | -58.06% |
Free Cash Flow | 2,051 | 2,722 | 1,270 | 1,144 | 3,382 |
Free Cash Flow Per Share | 13.94 | 18.66 | 8.72 | 7.84 | 22.61 |
Gross Margin | 78.95% | 78.00% | 74.24% | 77.61% | 80.79% |
Operating Margin | 28.55% | 26.51% | 19.30% | 29.67% | 31.29% |
Profit Margin | 13.07% | 16.87% | 11.80% | 29.95% | 14.17% |
Free Cash Flow Margin | 20.73% | 28.13% | 12.91% | 11.24% | 30.80% |
EBITDA | 3,604 | 3,239 | 2,394 | 3,537 | 3,923 |
EBITDA Margin | 36.44% | 33.47% | 24.34% | 34.77% | 35.73% |
D&A For EBITDA | 779.9 | 673.2 | 494.8 | 518.4 | 487.7 |
EBIT | 2,824 | 2,566 | 1,899 | 3,019 | 3,436 |
EBIT Margin | 28.55% | 26.51% | 19.30% | 29.67% | 31.29% |
Effective Tax Rate | 16.93% | 14.37% | 10.43% | 17.61% | 2.95% |
Revenue as Reported | 9,891 | 9,676 | 9,836 | 10,173 | 10,982 |
Advertising Expenses | 71.9 | 66.8 | 71.4 | 54.1 | 98.7 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.